A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)

NCT07264634 · clinicaltrials.gov ↗

RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypoparathyroidism

Interventions

DRUG: Palopegteriparatide

Sponsor

Ascendis Pharma A/S